RxDoctor Payments DataLook up a doctor →

Clifford Bragg, NP

Nurse Practitioner · Fort Mohave, AZNPI 1912486523

Payments from drug & device makers

$15,915in general payments, 2019–2025

Across 664 payments — averaging $23.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$3K
  • Sobi, Inc$1K
  • AstraZeneca$1K
  • Johnson & Johnson$983
  • Astellas Pharma US Inc$941
  • Incyte Corporation$576
  • plus $8K from 54 others

What the payments were for

  • Food & beverage$11,33671%
  • Education$1,88112%
  • Other$2,69817%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis51$3,009
Sobi, Inc67$1,195
AstraZeneca(2 entities)48$1,093
Johnson & Johnson(2 entities)54$983
Astellas Pharma US Inc19$941
Incyte Corporation26$576
Amgen31$540
Seagen Inc.19$537
Bristol Myers Squibb31$531
Lilly USA, LLC29$489
AbbVie22$430
Merck17$392
Bayer20$361
AVEO Pharmaceuticals, Inc.7$288
Daiichi Sankyo Inc.23$279
Pfizer11$229
E.r. Squibb & Sons, L.L.C.11$220
Eisai Inc.8$172
EMD Serono, Inc.9$171
Beigene USA, Inc.7$170
Tersera Therapeutics LLC9$165
Pharmacyclics LLC, An Abbvie Company8$163
Sanofi9$161
Gilead4$159
Pharmacosmos Therapeutics Inc.7$150
Genmab U.S., Inc.6$132
Genentech USA, Inc.6$119
Rigel Pharmaceuticals, Inc.5$119
Boehringer Ingelheim5$115
Boston Scientific1$114
Dova Pharmaceuticals4$113
Adaptive Biotechnologies Corporation5$112
Regeneron Healthcare Solutions, Inc.6$108
Mirati Therapeutics, Inc.5$104
Agios Pharmaceuticals, Inc.5$94
Stemline Therapeutics Inc.5$93
Takeda Pharmaceuticals U.S.A., Inc.4$84
Coherus Oncology, Inc.4$83
Ipsen Biopharmaceuticals, Inc4$81
Blueprint Medicines Corporation3$78
Myovant Sciences Inc.4$78
Heron Therapeutics, Inc.3$74
GSK3$64
AMAG Pharmaceuticals, Inc.4$63
Geron Corporation2$62
Pharmaessentia USA Corporation3$59
Progenics Pharmaceuticals, Inc.3$56
Clovis Oncology, Inc.2$47
Sumitomo Pharma America, Inc.2$45
Jazz Pharmaceuticals Inc.2$44
Exelixis Inc.2$43
G1 Therapeutics, Inc.2$36
Array Biopharma Inc2$34
Puma Biotechnology, Inc.2$33
Kyowa Kirin, Inc.2$32
Karyopharm Therapeutics Inc.2$24
Taiho Oncology, Inc.1$24
Verity Pharmaceuticals Inc.1$22
Alnylam Pharmaceuticals Inc.1$20
Beone Medicines USA, Inc.1$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,915 in reported general payments places this provider in the 95th percentile of 1,719 nurse practitioner providers in Arizona.

See all nurse practitioner providers in Arizona

Medicare billing

Part B allowed, 2024
$44,292
Medicare patients
311
Services billed
519

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JakafiRuxolitinib Phosphate129$2,155,052
ImbruvicaIbrutinib43$701,566
Lenalidomide35$541,950
ProcritEpoetin Alfa115$406,416
TibsovoIvosidenib11$364,332
NinlaroIxazomib Citrate28$352,448
JaypircaPirtobrutinib12$265,932
VerzenioAbemaciclib17$260,660
Somatuline DepotLanreotide Acetate19$175,367
ImfinziDurvalumab13$163,640
Neulasta OnproPegfilgrastim26$159,321
KeytrudaPembrolizumab14$155,428
Lupron DepotLeuprolide Acetate23$128,355
OctagamImmun Globg(Igg)/Malt/Iga Ov5020$114,063
EliquisApixaban92$93,392

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Incyte CorporationJakafi$576$2,155,052129 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$163$701,56643 claims
Lilly USA, LLCJaypirca, Verzenio$489$526,59229 claims
Johnson & JohnsonProcrit, Xarelto$983$420,046130 claims
Takeda Pharmaceuticals U.S.A., Inc.Ninlaro$84$352,44828 claims
PfizerOctagam, Eliquis$229$207,455112 claims
Ipsen Biopharmaceuticals, IncSomatuline Depot$81$175,36719 claims
AstraZenecaImfinzi$1,093$163,64013 claims
MerckKeytruda$392$155,42814 claims
AbbVieLupron Depot$430$128,35523 claims
AmgenProlia, Xgeva$540$95,48144 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,719 nurse practitioner providers in Arizona.

Other nurse practitioner in Fort Mohave

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →